Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: GlobalData
$250.00
Provider: Ford Investor Services, Inc.
$12.00
Provider: Plunkett Research, Ltd.
$99.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Nephros Inc Announces Completion Of Rights Offering


Thursday, 23 May 2013 04:30pm EDT 

Nephros Inc announced that the completion of its rights offering. In addition, the concurrent temporary reduction in exercise price for the Company's March 2011 warrants expired on May 17, 2013. Nephros estimates that it will receive gross proceeds of $3.0 million from the rights offering. A portion of the proceeds will be used for the repayment of the $1.3 million note, plus all accrued interest thereon ($46,800), issued to Lambda Investors LLC, Nephros' largest stockholder, in February 2013 in connection with its loan to Nephros, the payment of an 8% sourcing/transaction fee ($104,000) in respect of the note and an aggregate of $100,000 for reimbursement of Lambda Investors' legal fees incurred in connection with the loan and the rights offering. Based on holders of subscription rights who exercised their basic subscription rights in full and subscribed for additional shares of Common Stock pursuant to the over subscription privilege, the rights offering was fully subscribed. Nephros expects to issue a total of 5,000,000 shares of common stock to the holders of subscription rights who validly exercised their subscription rights and paid the subscription price in full, including pursuant to the exercise of the over subscription privilege. 

Company Quote

1.15
-0.02 -1.71%
23 Jul 2014